Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 3/20 | 0.42 |
| ▸ | CTSK | P43235 | 3/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL556588 | 1.00 | MEN1 (0.46) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL1457816 | 1.00 | MEN1 (0.46) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL12274268 | 0.85 | CA1 (0.51) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL18290278 | 0.82 | MEN1 (0.47) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL1105702 | 0.82 | PCSK9 (0.50) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL6563149 | 0.82 | MEN1 (0.50) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL13617295 | 0.81 | CA1 (0.53) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL22923920 | 0.81 | MEN1 (0.44) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL20480002 | 0.81 | KMT2A (0.47) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL18463269 | 0.81 | MEN1 (0.56) | MEN1GAAKMT2ATDP1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4620959-A1 | CYCLIC COMPOUNDS USED AS MULTI-TARGET KINASE INHIBITORS AND PREPARATION METHOD THEREFOR | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) | 2025-09-24 | — | — | EP | disclosed |
| WO-2021250541-A1 | SPIRO COMPOUNDS AS MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2021-12-16 | — | — | WO | disclosed |
| EP-3668550-A1 | BICYCLIC PEPTIDE LIGAND PRR-A CONJUGATES AND USES THEREOF | Bicyclerd Limited (GB) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019034868-A1 | BICYCLIC PEPTIDE LIGAND PRR-A CONJUGATES AND USES THEREOF | Bicyclerd Limited (GB) | 2019-02-21 | — | — | WO | disclosed |
| US-20170291905-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-12 | — | — | US | disclosed |
| EP-2970134-A1 | PYRAZOLE DERIVATIVES ASPRMT1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2970132-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014153226-A9 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-01-08 | — | — | WO | disclosed |
| WO-2014153226-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014153090-A1 | PYRAZOLE DERIVATIVES ASPRMT1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-1993020044-A1 | 1,4 NAPHTHOQUINONE DERIVTIVES WITH ANTI-PROTOZOAL AND ANTI-PARASITIC ACTIVITY | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170291905-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT6 | MEN1 1124/4885GAA 390/4885KMT2A 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.